Sign in
4

Changes in Ownership

Bicara Therapeutics Inc. Filed Acc 0001470831-26-000700

Chief Financial Officer sold 28,000 shares at an average $28.85 ($807,672)

  • Chief Financial Officer acquired 12,500 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Hyep Ivan Chief Financial Officer 2026-07-08 Option exercise 10b5-1 +12,500 $3.79 $47,373 157,855 D
Hyep Ivan Chief Financial Officer 2026-07-08 Sale 10b5-1 −22,757 $28.60 $650,896 135,098 D
Hyep Ivan Chief Financial Officer 2026-07-08 Sale 10b5-1 −4,413 $29.82 $131,616 130,685 D
Hyep Ivan Chief Financial Officer 2026-07-08 Sale 10b5-1 −830 $30.31 $25,160 129,855 D
Derivatives
Hyep Ivan Chief Financial Officer 2026-07-08 Option exercise · Stock Option (Right to Buy) 10b5-1 −11,592 58,992 D
Hyep Ivan Chief Financial Officer 2026-07-08 Option exercise · Stock Option (Right to Buy) 10b5-1 −908 38,836 D
Open-market sales · 28,000 sh · avg $28.85 · $807,672
Loading xslF345X06/wk-form4_1783714240.xml…